Interleukin‐2‐inducible kinase represents a novel therapeutic target for NK/T‐cell lymphoma treatment
Jinglin Cao,Dingyao Hu,Heng Yu,M. Li,Y. Ye,D. Wang,Jianhui Wu,Lan Mi,Shaokun Shu,Wu H,X. Wang,Min Deng,Chao Han,W. Zhang,Ning Ding,Yun Xie,Yuqin Song,Jun Zhu
DOI: https://doi.org/10.1002/hon.3164_416
IF: 4.85
2023-01-01
Hematological Oncology
Abstract:Background: Natural killer T-cell lymphoma (NKTCL) is a highly aggressive non-Hodgkin lymphoma with more incidence in Asian and South American populations. Patients suffered from advanced stage disease have limited treatment options and dismal prognosis. Therefore, the development of novel therapeutic targets for the treatment of this debilitating disease is urgently needed. ITK (interleukin-2-inducible kinase, ITK), one of the Tec kinase family, is predominantly expressed in T and natural killer T cells. Though redundant ITK expression was reported in NKTCL, the role of ITK in NKTCL has not been fully investigated. In this study, we elucidate the important role of ITK within the pathogenesis of NK/T cell lymphoma. Methods: Expression level of ITK and p-ITK in NKTCL cell line and patients were performed by immunoblotting and immunohistochemistry, respectively. The lentivirus containing dox-induced ITK targeting shRNA or ITK overexpression plasmid were used to mediate conditional ITK knockdown or stable overexpression of ITK. NKTCL cell line stably transfected dox-induced shRNA or control shRNA plasmids was engrafted in opposite lateral of the same NCG mice to investigate the effect of ITK knockdown in vivo, 4 mg/mL dox in drinking water was administrated to induce ITK knockdown in vivo. The cell viability of tumor cells was analyzed through Cell Titer-Glo® Luminescent Cell Viability Assay. Soft agarose colony forming assay was employed to determine the influence of ITK inhibitor on colony-forming ability of NKTCL cell lines. Results: The expression level of ITK were first analyzed in NKTCL cell lines (KHYG-1, YT, NK-YS and YTS). The KHYG-1 and YT cell showed high level of phosphorylation of ITK activation. Meanwhile, the activation and expression of ITK protein could also be observed in NKTCL patients (n = 17). Next the ITK overexpression plasmid were transfected into NK-YS and YTS cells, which promoted the proliferation of tumor cells. On the other hand, the conditional knockdown of ITK significantly suppressed the growth of KHYG-1 and YT cells. Furthermore, in vivo ablation of ITK in YT mouse model obviously delayed the progression of NKTCL tumors, showing smaller tumor size and lower weight compared with control group, highlighting ITK is a new fragility of NKTCL cells. To further validate this therapeutic effect, NKTCL cells were treated with ITK inhibitors for 24h, 48h and 72h in vitro, The ITK inhibitors repressed the viability of these NKTCL cells in a concentration and time-dependent manner. Furthermore, ITK inhibitors treatment abolished the colony formation of NKTCL cells, which indicated the ITK might represent the potential therapeutic target for NKT cell lymphoma. Taking together, targeting ITK is a promising strategy for treatment NKTCL. Encore Abstract - previously submitted to regional or national meetings (up to <1’000 attendees) Keywords: Aggressive T-cell non-Hodgkin lymphoma, Molecular Targeted Therapies No conflicts of interests pertinent to the abstract.